-
Joincare Pharmaceutical Group Secures USD 100 Million Loan from IFC for Expansion
•
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a China-based pharmaceutical company, has announced securing a loan of USD 100 million from the International Finance Corporation (IFC). The funds will be directed towards the construction of new manufacturing and research and development facilities in Henan and Guangdong provinces. Additionally, the…
-
South Korean Duo GC Wellbeing and YooYoung Pharmaceutical Target Chinese Filler Market
•
South Korean health and functional food manufacturer GC Wellbeing and YooYoung Pharmaceutical have formed a strategic partnership to enter the Chinese filler market, as reported by Koreabiomed.com. YooYoung, an established manufacturer of hyaluronic acid (HA) formulations, will utilize its HIVE (Hybrid Technology Improving Viscosity and Elasticity) technology to develop a…
-
TYK Medicines Files for IPO on HKSE Amid Rising Losses and Expanding Drug Pipeline
•
Zhejiang-based TYK Medicines Inc. (HKG: 2410) has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange (HKSE). The company reported revenues of RMB 44 million and a loss of RMB 312 million in 2022, primarily generated through a licensing agreement with Livzon Pharma. In the first…
-
Bristol Myers Squibb’s Subcutaneous Opdivo Shows Noninferiority in Phase III ccRCC Trial
•
Bristol Myers Squibb (BMS; NYSE: BMY) this week announced preliminary Phase III data demonstrating that its subcutaneous formulation of Opdivo (nivolumab), developed in partnership with Halozyme Therapeutics (NASDAQ: HALO), is noninferior to the intravenous version for patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC). The equivalence trial…
-
Blue Sail Medical Secures RMB 900 Million Investment for R&D and Capacity Expansion
•
Blue Sail Medical Co., Ltd (SHE: 002382) has announced that its wholly owned subsidiary, Blue Sail Biosensors Medical Technology, has secured strategic investments totaling RMB 900 million from Capital Health Industry (Beijing) Fund and two other investors. The funds will be allocated to enhance product research and development as well…
-
3D Medicines Partners with Sino Cellbiomed to Advance Tumor Immunotherapy Development
•
3D Medicines (HKG: 1244), a China-based oncology specialist, has entered into a partnership with Sino Cellbiomed, a Qingdao-based cell therapy firm, to collaborate on the development of tumor immunotherapies. Financial terms of the agreement have not been disclosed. Since its debut on the Hong Kong Stock Exchange in December 2022,…
-
Mindray to Acquire 21.12% Stake in APT Medical for RMB 6.652 Billion
•
Mindray (SHE: 300760), a leading China-based medtech firm, has announced plans to acquire a 21.12% stake in APT Medical Inc., a Shenzhen-based specialist in cardiac electrophysiology that went public on Shanghai’s STAR market in 2021. The acquisition will cost Mindray approximately RMB 6.652 billion (USD 926.6 million). Additionally, Mindray will…
-
Johnson & Johnson’s Rybrevant and Lazertinib Filings Accepted for Review by CDE
•
The Center for Drug Evaluation (CDE) has confirmed that Johnson & Johnson’s (J&J, NYSE: JNJ) market filings for Rybrevant (amivantamab) and lazertinib, designated as JXSS2400004 and JXHS2400009 respectively, have been accepted for review. Amivantamab-vmjw, a bispecific antibody targeting EGFR and MET, received its initial approval in May 2021 for the…
